Literature DB >> 24666102

Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register.

Andreas Thorstenson1, Martin Bergman, Ann-Helén Scherman-Plogell, Soheila Hosseinnia, Börje Ljungberg, Jan Adolfsson, Sven Lundstam.   

Abstract

OBJECTIVE: Tumour characteristics, preoperative work-up and surgical treatment in patients diagnosed with renal cell carcinoma (RCC) between 2005 and 2010, and changes over time were studied in a national population-based cohort.
MATERIAL AND METHODS: The National Swedish Kidney Cancer Register (NSKCR) contains information on histopathology, Fuhrman grade and clinical stage at presentation, and on the preoperative work-up and surgical treatment of patients with RCC. Between 2005 and 2010, 5553 RCC patients were registered in the NSKCR, 99% of those registered in the National Cancer Registry.
RESULTS: During the study period the mean tumour size decreased from 70 to 64 mm (p = 0.024) and the frequency of metastatic RCC decreased from 22% to 15% (p < 0.001). The use of preoperative chest computed tomography increased from 59% to 84%. In total, 4229 (76%) patients were treated with curative intent, 3453 (82%) underwent radical nephrectomy, 606 (14%) partial nephrectomy (PN) and 170 (4%) cryotherapy or radiofrequency ablation. In tumours up to 4 cm, PN was performed in 33% of the surgically treated patients. PN irrespective of size increased from 8% to 20% and laparoscopic nephrectomy increased from 6% to 17% during the period. In patients with metastatic RCC, 55% underwent cytoreductive nephrectomy.
CONCLUSIONS: The NSKCR explores population-based data on the clinical handling of patients with RCC. This study, between 2005 and 2010, shows significant decrease in tumour size and metastatic RCC at presentation, a more complete preoperative work-up, and significantly increased use of PN and laparoscopic nephrectomy in Sweden.

Entities:  

Keywords:  distant metastasis; lymph-node metastasis; population-based; renal cell carcinoma; survival; tumour category; tumour size

Mesh:

Year:  2014        PMID: 24666102     DOI: 10.3109/21681805.2013.864698

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  25 in total

1.  [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]

Authors:  N Gilbert; A S Merseburger; M W Kramer
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

2.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

3.  External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Lorenzo Marconi; Roderick de Bruijn; Erik van Werkhoven; Christian Beisland; Kate Fife; Axel Heidenreich; Anil Kapoor; Jose Karam; Caroline Kauffmann; Tobias Klatte; Boerje Ljungberg; Surena Matin; Daniel Sjoberg; Michael Staehler; Grant D Stewart; Simon Tanguay; Robert Uzzo; Sarah Welsh; Lori Wood; Chris Wood; Axel Bex
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

Review 4.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.

Authors:  Oscar Rodriguez Faba; Sabine D Brookman-May; Estefania Linares; Alberto Breda; Francesca Pisano; José Daniel Subiela; Francesco Sanguedolce; Maurizio Brausi; Joan Palou
Journal:  World J Urol       Date:  2017-07-12       Impact factor: 4.226

5.  Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Authors:  Charles Van Praet; Charlotte Slots; Nikhil Vasdev; Sylvie Rottey; Valérie Fonteyne; Iulia Andras; Maarten Albersen; Gert De Meerleer; Axel Bex; Karel Decaestecker
Journal:  Turk J Urol       Date:  2021-02

6.  Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

Authors:  Bernhard Brehmer; Caroline Kauffmann; Christian Blank; Axel Heidenreich; Axel Bex
Journal:  World J Urol       Date:  2016-06-10       Impact factor: 4.226

7.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Authors:  Saeed Dabestani; Andreas Thorstenson; Per Lindblad; Ulrika Harmenberg; Börje Ljungberg; Sven Lundstam
Journal:  World J Urol       Date:  2016-02-05       Impact factor: 4.226

8.  Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer.

Authors:  Rong Hu; Rohit Gupta; Zheyu Wang; Congzhou Wang; Hongcheng Sun; Srikanth Singamaneni; Evan D Kharasch; Jeremiah J Morrissey
Journal:  Kidney Int       Date:  2019-09-03       Impact factor: 10.612

9.  DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).

Authors:  Emma Andersson Evelönn; Sofie Degerman; Linda Köhn; Mattias Landfors; Börje Ljungberg; Göran Roos
Journal:  Tumour Biol       Date:  2016-01-30

10.  Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Authors:  Kari Hemminki; Asta Försti; Akseli Hemminki; Börje Ljungberg; Otto Hemminki
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.